Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis
Washington University School of Medicine
Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Description
All participants who are eligible and provide informed consent will complete an initial study visit, which includes a research blood collection and cognitive assessments. Depending on the results of the cognitive assessments, participants will complete follow-up visits annually or biennially for additional cognitive testing, research blood collections, and potential clinical testing for Alzheimer's disease as determined by the participant's medical provider.
Eligibility
- Age range
- 60+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * At least 60 years of age * 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider * All SEABIRD participants will be invited to participate regardless of their cognitive status Exclusion Criteria: * Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment * Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection * Taking a d…
Interventions
- Diagnostic TestClinical tau PET
Tau PET (flortaucipir)
- Diagnostic TestClinical amyloid test
Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
- OtherResearch blood collection
Research blood assays for amyloid, tau, and neurodegeneration
- OtherCognitive assessments
Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
Location
- Washington University School of MedicineSt Louis, Missouri